Skip to main content

Table 2 Patient characteristics

From: A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine

 

Pregabalin

Duloxetine

 
 

N = 446

N = 446

 
 

n

%

n

%

P value*

Age, years (categorical)

    

0.1304

18-29

0

0.0

0

0.0

 

30-39

7

1.6

1

0.2

40-49

27

6.1

26

5.8

50-59

73

16.4

86

19.3

60-69

144

32.3

159

35.7

70-79

150

33.6

126

28.3

80-89

45

10.1

48

10.8

Gender

    

0.5854

Male

185

41.5

177

39.7

 

Female

261

58.5

269

60.3

Race/Ethnicity

    

0.7265

White

363

81.4

353

79.1

 

Black

58

13.0

69

15.5

Hispanic

13

2.9

14

3.1

Other

12

2.7

10

2.2

Geographic Region

    

0.6759

Northeast

5

1.1

5

1.1

 

Midwest

78

17.5

78

17.5

South

338

75.5

333

74.7

West

25

5.6

30

6.7

Low Income Status

87

19.5

92

20.6

0.6814

Dual Eligibility Status

52

11.7

56

12.6

0.6759

 

Mean

SD

Mean

SD

 

Age, years (continuous)

66.7

10.7

66.7

10.4

0.5924

Propensity Score

0.47

0.14

0.47

0.14

0.9931

  1. *All P values for categorical variables calculated using chi -square tests. All P values for continuous variables calculated using Wilcoxon rank-sum tests.
  2. SD, Standard Deviation.
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us